Induction Study #2 - A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease
Phase of Trial: Phase III
Latest Information Update: 18 Feb 2019
At a glance
- Drugs Ozanimod (Primary)
- Indications Crohn's disease
- Focus Registrational; Therapeutic Use
- Sponsors Celgene Corporation
- 07 Dec 2018 Planned End Date changed from 31 Jul 2020 to 30 Aug 2020.
- 06 Sep 2018 Planned End Date changed from 31 Mar 2020 to 31 Jul 2020.
- 06 Sep 2018 Status changed from not yet recruiting to recruiting.